Literature DB >> 12874330

Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

A Rainczuk1, T Scorza, P M Smooker, T W Spithill.   

Abstract

It has been proposed that a multivalent malaria vaccine is necessary to mimic the naturally acquired resistance to this disease observed in humans. A major experimental challenge is to identify the optimal components to be used in such a multivalent vaccine. Expression library immunization (ELI) is a method for screening genomes of a pathogen to identify novel combinations of vaccine sequences. Here we describe immune responses associated with, and the protective efficacy of, genomic Plasmodium chabaudi adami DS expression libraries constructed in VR1020 (secretory), monocyte chemotactic protein-3 (chemoattractant), and cytotoxic T lymphocyte antigen 4 (lymph node-targeting) DNA vaccine vectors. With splenocytes from vaccinated mice, specific T-cell responses, as well as gamma interferon and interleukin-4 production, were observed after stimulation with P. chabaudi adami-infected erythrocytes, demonstrating the specificity of genomic library vaccination for two of the three libraries constructed. Sera obtained from mice vaccinated with genomic libraries promoted the opsonization of P. chabaudi adami-infected erythrocytes by murine macrophages in vitro, further demonstrating the induction of malaria-specific immune responses following ELI. Over three vaccine trials using biolistic delivery of the three libraries, protection after lethal challenge with P. chabaudi adami DS ranged from 33 to 50%. These results show that protective epitopes or antigens are expressed within the libraries and that ELI induces responses specific to P. chabaudi adami malaria. This study further demonstrates that ELI is a suitable approach for screening the malaria genome to identify the components of multivalent vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874330      PMCID: PMC166036          DOI: 10.1128/IAI.71.8.4506-4515.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge.

Authors:  G Deliyannis; J S Boyle; J L Brady; L E Brown; A M Lew
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

Review 3.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

4.  Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library.

Authors:  P C Melby; G B Ogden; H A Flores; W Zhao; C Geldmacher; N M Biediger; S K Ahuja; J Uranga; M Melendez
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Site-directed immune responses in DNA vaccines encoding ligand-antigen fusions.

Authors:  A M Lew; B J Brady; B J Boyle
Journal:  Vaccine       Date:  2000-02-25       Impact factor: 3.641

6.  Protection against mycoplasma infection using expression-library immunization.

Authors:  M A Barry; W C Lai; S A Johnston
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

7.  Specificity of the protective antibody response to apical membrane antigen 1.

Authors:  A N Hodder; P E Crewther; R F Anders
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.

Authors:  D R Drew; J S Boyle; A M Lew; M W Lightowlers; P J Chaplin; R A Strugnell
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

9.  CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.

Authors:  H Xu; A N Hodder; H Yan; P E Crewther; R F Anders; M F Good
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

10.  Antibody recognition of rodent malaria parasite antigens exposed at the infected erythrocyte surface: specificity of immunity generated in hyperimmune mice.

Authors:  M M Mota; K N Brown; V E Do Rosário; A A Holder; W Jarra
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

View more
  5 in total

1.  Macrophage migration inhibitory factor: a downregulator of early T cell-dependent IFN-gamma responses in Plasmodium chabaudi adami (556 KA)-infected mice.

Authors:  Diane Tshikudi Malu; Benoit Bélanger; François Desautels; Karine Kelendji; Esther Dalko; Jaime Sanchez-Dardon; Lin Leng; Richard Bucala; Abhay R Satoskar; Tatiana Scorza
Journal:  J Immunol       Date:  2011-04-25       Impact factor: 5.422

2.  Immune responses of NIH mice infected with avirulent and virulent strains of Plasmodium chabaudi adami single and mixed infections.

Authors:  M J Namazi; R S Phillips
Journal:  Korean J Parasitol       Date:  2010-03-18       Impact factor: 1.341

Review 3.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria.

Authors:  A Rainczuk; T Scorza; T W Spithill; P M Smooker
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.